Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
- Published: July 2010
The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy sales.
The commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers.
The entire branded cancer therapies market will grow from $40.6 billion in 2009 to $57.2 billion in 2019 at a CAGR of 3.5%
Reasons to Purchase
- Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2009 and 2019
- Acquire a detailed account of top-selling cancer brand dynamics and the events that drive and limit their market growth
- Acquire a detailed account of the key developers in the cancer therapy market and their forecast performance in the 7MM over the period 2009-2019